Time to reposition sulfonylureas in type 2 diabetes management in Indian context: A pragmatic practical approach

Sulfonylureas (SU) continue to be a vital therapeutic category of oral hypoglycemic agents (OHAs) for the management of type 2 diabetes mellitus (T2DM). Physicians consider modern SU (gliclazide and glimepiride) as “safe and smart” choices for T2DM management. The presence of multiple international...

Descripción completa

Detalles Bibliográficos
Autores principales: Das, Ashok Kumar, Saboo, Banshi, Chawla, Rajeev, Aravind, S. R., Rajput, Rajesh, Singh, Awadhesh K., Mukherjee, J. J., Jhingan, Ashok, Shah, Parag, Deshmukh, Vaishali, Kale, Shailaja, Jaggi, Shalini, Sridhar, G. R., Dhediya, Rajnish, Gaurav, Kumar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer India 2023
Materias:
Guidelines
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10113130/
https://www.ncbi.nlm.nih.gov/pubmed/37360324
http://dx.doi.org/10.1007/s13410-023-01192-6
_version_ 1785027769009176576
author Das, Ashok Kumar
Saboo, Banshi
Chawla, Rajeev
Aravind, S. R.
Rajput, Rajesh
Singh, Awadhesh K.
Mukherjee, J. J.
Jhingan, Ashok
Shah, Parag
Deshmukh, Vaishali
Kale, Shailaja
Jaggi, Shalini
Sridhar, G. R.
Dhediya, Rajnish
Gaurav, Kumar
author_facet Das, Ashok Kumar
Saboo, Banshi
Chawla, Rajeev
Aravind, S. R.
Rajput, Rajesh
Singh, Awadhesh K.
Mukherjee, J. J.
Jhingan, Ashok
Shah, Parag
Deshmukh, Vaishali
Kale, Shailaja
Jaggi, Shalini
Sridhar, G. R.
Dhediya, Rajnish
Gaurav, Kumar
author_sort Das, Ashok Kumar
collection PubMed
description Sulfonylureas (SU) continue to be a vital therapeutic category of oral hypoglycemic agents (OHAs) for the management of type 2 diabetes mellitus (T2DM). Physicians consider modern SU (gliclazide and glimepiride) as “safe and smart” choices for T2DM management. The presence of multiple international guidelines and scarcity of a national guideline may contribute to the challenges faced by few physicians in choosing the right therapeutic strategy. The role of SU in diabetes management is explicit, and the present consensus aims to emphasize the benefits and reposition SU in India. This pragmatic, practical approach aims to define expert recommendations for the physicians to improve caregivers’ knowledge of the management of T2DM, leading to superior patient outcomes.
format Online
Article
Text
id pubmed-10113130
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Springer India
record_format MEDLINE/PubMed
spelling pubmed-101131302023-04-20 Time to reposition sulfonylureas in type 2 diabetes management in Indian context: A pragmatic practical approach Das, Ashok Kumar Saboo, Banshi Chawla, Rajeev Aravind, S. R. Rajput, Rajesh Singh, Awadhesh K. Mukherjee, J. J. Jhingan, Ashok Shah, Parag Deshmukh, Vaishali Kale, Shailaja Jaggi, Shalini Sridhar, G. R. Dhediya, Rajnish Gaurav, Kumar Int J Diabetes Dev Ctries Guidelines Sulfonylureas (SU) continue to be a vital therapeutic category of oral hypoglycemic agents (OHAs) for the management of type 2 diabetes mellitus (T2DM). Physicians consider modern SU (gliclazide and glimepiride) as “safe and smart” choices for T2DM management. The presence of multiple international guidelines and scarcity of a national guideline may contribute to the challenges faced by few physicians in choosing the right therapeutic strategy. The role of SU in diabetes management is explicit, and the present consensus aims to emphasize the benefits and reposition SU in India. This pragmatic, practical approach aims to define expert recommendations for the physicians to improve caregivers’ knowledge of the management of T2DM, leading to superior patient outcomes. Springer India 2023-04-19 /pmc/articles/PMC10113130/ /pubmed/37360324 http://dx.doi.org/10.1007/s13410-023-01192-6 Text en © The Author(s), under exclusive licence to Research Society for Study of Diabetes in India 2023, Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Guidelines
Das, Ashok Kumar
Saboo, Banshi
Chawla, Rajeev
Aravind, S. R.
Rajput, Rajesh
Singh, Awadhesh K.
Mukherjee, J. J.
Jhingan, Ashok
Shah, Parag
Deshmukh, Vaishali
Kale, Shailaja
Jaggi, Shalini
Sridhar, G. R.
Dhediya, Rajnish
Gaurav, Kumar
Time to reposition sulfonylureas in type 2 diabetes management in Indian context: A pragmatic practical approach
title Time to reposition sulfonylureas in type 2 diabetes management in Indian context: A pragmatic practical approach
title_full Time to reposition sulfonylureas in type 2 diabetes management in Indian context: A pragmatic practical approach
title_fullStr Time to reposition sulfonylureas in type 2 diabetes management in Indian context: A pragmatic practical approach
title_full_unstemmed Time to reposition sulfonylureas in type 2 diabetes management in Indian context: A pragmatic practical approach
title_short Time to reposition sulfonylureas in type 2 diabetes management in Indian context: A pragmatic practical approach
title_sort time to reposition sulfonylureas in type 2 diabetes management in indian context: a pragmatic practical approach
topic Guidelines
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10113130/
https://www.ncbi.nlm.nih.gov/pubmed/37360324
http://dx.doi.org/10.1007/s13410-023-01192-6
work_keys_str_mv AT dasashokkumar timetorepositionsulfonylureasintype2diabetesmanagementinindiancontextapragmaticpracticalapproach
AT saboobanshi timetorepositionsulfonylureasintype2diabetesmanagementinindiancontextapragmaticpracticalapproach
AT chawlarajeev timetorepositionsulfonylureasintype2diabetesmanagementinindiancontextapragmaticpracticalapproach
AT aravindsr timetorepositionsulfonylureasintype2diabetesmanagementinindiancontextapragmaticpracticalapproach
AT rajputrajesh timetorepositionsulfonylureasintype2diabetesmanagementinindiancontextapragmaticpracticalapproach
AT singhawadheshk timetorepositionsulfonylureasintype2diabetesmanagementinindiancontextapragmaticpracticalapproach
AT mukherjeejj timetorepositionsulfonylureasintype2diabetesmanagementinindiancontextapragmaticpracticalapproach
AT jhinganashok timetorepositionsulfonylureasintype2diabetesmanagementinindiancontextapragmaticpracticalapproach
AT shahparag timetorepositionsulfonylureasintype2diabetesmanagementinindiancontextapragmaticpracticalapproach
AT deshmukhvaishali timetorepositionsulfonylureasintype2diabetesmanagementinindiancontextapragmaticpracticalapproach
AT kaleshailaja timetorepositionsulfonylureasintype2diabetesmanagementinindiancontextapragmaticpracticalapproach
AT jaggishalini timetorepositionsulfonylureasintype2diabetesmanagementinindiancontextapragmaticpracticalapproach
AT sridhargr timetorepositionsulfonylureasintype2diabetesmanagementinindiancontextapragmaticpracticalapproach
AT dhediyarajnish timetorepositionsulfonylureasintype2diabetesmanagementinindiancontextapragmaticpracticalapproach
AT gauravkumar timetorepositionsulfonylureasintype2diabetesmanagementinindiancontextapragmaticpracticalapproach

Ejemplares similares